Repligen Corp.

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Health Technology » Pharmaceuticals Major
JNJJohnson & Johnson 0.45%166.930.7%$1253.55m
LLYEli Lilly & Co. 0.18%311.431.1%$814.08m
BMYBristol-Myers Squibb Co. -0.73%70.771.0%$778.85m
PFEPfizer Inc. -1.10%44.080.9%$769.71m
ABBVAbbVie, Inc. 0.04%143.061.9%$735.85m
MRKMerck & Co., Inc. -0.81%86.800.7%$691.58m
AZNAstraZeneca Plc -3.07%54.581.0%$397.16m
ALNYAlnylam Pharmaceuticals, Inc. -0.95%200.788.2%$207.03m
NVSNovartis AG -1.47%76.010.2%$201.13m
GBTGlobal Blood Therapeutics, Inc. 0.03%67.995.4%$199.71m
GSKGSK Plc -2.13%29.370.3%$192.16m
NVONovo Nordisk A/S -0.40%97.920.1%$170.11m
HZNPHorizon Therapeutics Plc 0.54%62.975.4%$156.21m
SGENSeagen Inc. -0.96%139.205.7%$152.48m
SRPTSarepta Therapeutics, Inc. -2.42%108.1912.4%$128.76m

Company Profile

Repligen Corp. provides bioprocessing technologies and solutions used in the process of manufacturing biologic drugs. It serves through the following product lines: Chromatography, Filtration, Process Analytics, and Proteins. The Chromatography product includes a range of products used in the downstream purification and quality control of biological drugs. The Filtration products offer a number of advantages to manufacturers of biologic drugs at volumes that span from pilot studies to clinical and commercial-scale production. The Process Analytics products complement and support filtration, chromatography and proteins in-line absorbance measurements allowing for the determination of protein concentration in filtration, chromatography formulation and fill-finish applications. The Proteins product franchise is represented by Protein A affinity ligands, which are a critical component of Protein A chromatography resins used in downstream purification of virtually all mAb-based drugs on the market. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.